Table 2. Summary of the efficacy.
| Group | TFTD→Rego group | TFTD+Bev→Rego group | Rego→TFTD group | |||
|---|---|---|---|---|---|---|
| (N = 27) | (N = 13) | (N = 29) | ||||
| Agent | Precedent TFTD | Subsequent Rego | Precedent TFTD+Bev | Subsequent Rego | Precedent Rego | Subsequent TFTD |
| ORR (number of pts, (%)) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (3) |
| DCR (number of pts, (%)) | 3 (11) | 6 (22) | 3 (23) | 4 (31) | 7 (24) | 6 (21) |
| median PFS (months) | 1.87 | 1.93 | 2.07 | 1.47 | 1.87 | 1.73 |
| (1.60–2.07) | (1.53–2.33) | (1.63–2.67) | (1.00–2.17) | (1.37–2.40) | (1.00–2.80) | |
| (95% CI) | ||||||
| median T-PFS (months) | 4.43 | 4.20 | 4.23 | |||
| (3.83–5.60) | (3.47–5.37) | (2.90–5.53) | ||||
| (95% CI) | ||||||
| median OS (months) | 10.4 | 10.3 | 10.1 | |||
| (4.83–12.8) | (4.77-not achieved) | (6.27–11.8) | ||||
| (95% CI) | ||||||
| median TGR (%/month) | 50.9 | 32.7 | 25.4 | 36.1 | 40.8 | 24.4 |
| (-6.1 to 205.7) | (-36.0 to 143.4) | (-4.2 to 132.9) | (8.9 to 49.0) | (-11.1 to 173.8) | (-55.6 to 302.9) | |
| (range) | ||||||
| Number of pts with decrease of TGR | 20 | 6 | 19 | |||
| (74%) | (46%) | (66%) | ||||
| median TGK (mm/month) (range) | 8.76 | 7.79 | 7.49 | 9.92 | 8.02 | 7.20 |
| (-1.0 to 45.6) | (-2.8 to 83.3) | (-1.8 to 17.4) | (2.0 to 19.7) | (-6.2 to 22.1) | (-5.6 to 33.9) | |
| Number of pts with decrease of TGK | 15 | 4 | 17 | |||
| (56%) | (31%) | (59%) | ||||
Abbreviations: Rego, regorafenib; TFTD, trifluridine/tipiracil; Bev, bevacizumab; ORR, objective response rate; DCR, disease control rate; PFS, progression-free survival; T-PFS, two drugs PFS; OS, overall survival; TGR, tumor growth rate; TGK, tumor growth kinetics; pts, patients